INS and type 2 diabetes mellitus: An open-label clinical trial in adults without known atherosclerotic cardiovascular disease or T2DM at the baseline investigated the role of atorvastatin in the physiological mechanism for T2DM risk, proving that high-intensity atorvastatin for 10 weeks increases insulin resistance and insulin secretion [25].